Idiopathic inflammatory myopathies (IIM) represent a heterogeneous group of autoimmune disorders primarily characterised by progressive muscle weakness and inflammation, but with potential involvement ...

Jackson, MS - New research suggests that mycophenolate mofetil (MMF) can be used in the management of autoimmune inflammatory myopathy. The finding, published in the March 2005 issue of Rheumatology, ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

History gathering should solicit the patient’s abilities or limitations with these activities of daily living (ADLs). The patient may have mild arthralgias. Lungs are the most common extra muscular ...

Physician sentiment captured in Spherix Global Insights’ research highlights high expectations for dual TYK2/JAK1 inhibition, ...

Despite modern medical therapies, multiorgan idiopathic inflammatory myopathies (IIM) are associated with reduced quality of life and life expectancy. A systematic review of all published ...

Malignancies may initially present with muscle weakness and elevated muscle enzymes. Age and gender-specific cancer screening should be completed or updated in those with a myopathic process. 9,10 ...

Idiopathic inflammatory myopathies (IIM) are a group of conditions characterized by inflammation of muscles (myositis) and other body systems. Polymyositis and dermatomyositis are subtypes of IIM.

• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful ...

• Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) • Company ...

Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be initiated in the first quarter of 2025 Company plans to report initial clinical data from Phase ...